Table 2. Data Sharing for (Reporting Period)

Slides:

Advertisements

Similar presentations

K OREAN ADNI … WHERE ARE WE NOW Seol-Heui Han, MD, PhD. On behalf of Preparatory Committee for K-ADNI Seol-Heui Han, MD, PhD. On behalf of Preparatory.

Advertisements

The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing AUSTRALIAN ADNI. July 2010 UPDATE.

Department of Neurology, Mayo Clinic Arizona

December, NEED FOR VALIDATED BIOMARKERS FOR AD TRIALS Biomarkers useful in Phase 2 to make decisions about Phase 3 (e.g. doses) Biomarkers useful.

Tracking the East Midlands contribution to PD-PROBAND Nin Bajaj Clinical Director NPF International Centre of Excellence in PD, East Midlands Trent CLRN.

Alzheimer’s Disease Neuroimaging Initiative Neuropathology Core John C. Morris, MD Nigel J. Cairns, PhD, FRCPath Erin Householder, MS.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April

ADNI 3 Clinical Core Plans

CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.

Grant Review & Analysis Office Heather Offhaus, Director 11/1/2011.

Aging, Memory and Alzheimer’s Disease Kinga Szigeti, MD, PhD.

Alzheimer’s Disease Neuroimaging Initiative Neuropathology Core John C. Morris, MD Nigel J. Cairns, PhD, FRCPath Erin Franklin, MS Presented by: Beau Ances,

FTD Family Members Study & Post Mortem Study Alyson Negreira MGH Frontotemporal Disorders Unit.

EPAD update José Luis Molinuevo Worldwide-ADNI Update Meeting Friday, July 17, 2015 Washington, D.C.

Dept. of Radiology, Xuanwu Hospital, Capital Medical University Beijing: Emeil: 首都 Update of China-ADNI Kuncheng Li.

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.

Alzheimer’s Society, UK Our research programme

Update Arg-ADNI Gustavo E. Sevlever, Ricardo F. Allegri (*), Silvia Vázquez, Deborah R. Gustafson, Salvador M. Guinjoan, and Arg-ADNI group. Memory and.

COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.

Disclosure of research results: should policies be changed? Melanie B. Shulman, M.D., M.Phil. Clinical Associate Professor of Neurology and Psychiatry.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE Michael W. Weiner.

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar ADNI Steering Committee Meeting Washington, DC April.

Assessment and Diagnosis of Dementia Dr Alison Haddow.

Update Arg-ADNI Instituto de Investigaciones Neurológicas (FLENI)

High resolution MRI at 21.1 T of the hippocampus and temporal lobe white matter in the differential classification of Alzheimer’s Disease & Diffuse Lewy.

Cognitive Disorders Chapter 13 Nature of Cognitive Disorders: An Overview Perspectives on Cognitive Disorders Cognitive processes such as learning, memory,

Alzheimer’s Disease Genetics Initiative: Multiplex Family Study Jennifer Williamson Catania, MS Columbia University and NCRAD.

Clifford R Jack Jr MD Professor of Radiology

Kimiko Domoto-Reilly, MD Cognitive / Behavioral Neurology Fellow Massachusetts General Hospital & Brigham and Women’s Hospital.

Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.

Update of China-ADNI Kuncheng Li, MD. PhD.

ADNI3 Clinical core Paul Aisen Ron Petersen Mike Donohue

Aka STEEL VALLEY SENIORS SURVEY (SVSS)

Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease Mirjana Babić.

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Presenter: Dr. Patricio Chrem

Fran Borovečki3, Patrick R. Hof4, Nela Pivac2, Goran Šimić1*

Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar

COMBINATION OF CSF PROTEIN BIOMARKERS AND BDNF, IL10 AND IL6 GENOTYPES IN EARLY DIAGNOSIS OF ALZHEIMER’S DISEASE Mirjana Babić Leko1, Matea Nikolac Perković2,

Use of Amyloid PET Scan in Early Diagnosis of Alzheimer’s Disease in a Secondary Care Memory Clinic Niki Schoonenboom, MD PhD1, Mohammed Akarriou, MD2;

Mayo Clinic College of Medicine

Dementia Research and Enterprise at Liverpool John Moores University

Dementia: from molecules to minds

Fig. 11. Algorithm for differential diagnosis of cognitive impaired subjects by employing structural imaging. AD = Alzheimer's disease, BG = basal ganglia,

Your Title Here Authors’ Name(s) Here Background Table 1: Title

Volume 2, Issue 1, Pages (January 2016)

Imaging AD Progression Amyloid Imaging Agents.

Cognitive Disorders and Aging

PPMI in the Medical Literature

From the Indianapolis – Ibadan Dementia Research Project.

NACC Personnel NACC Director : Bud Kukull

Alzheimer’s Disease Core Center: Opportunities and Resources for the Wake Forest Community Suzanne Craft, PhD.

IDEAS Study. IDEAS Study IDEAS Research Team Study Overview.

PPMI – GOALS 2019 Ken Marek PPMI Annual Meeting May 3, 2018

ADNI3 Clinical core Paul Aisen Ron Petersen Mike Donohue

ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue

Ron Petersen & Paul Aisen

Presenter: Dr. Patricio Chrem

Update of China-ADNI Kuncheng Li, MD. PhD.

Chris Hyde Exeter Test Group.

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Argentina Arg-ADNI Ezequiel Surace, PhD.

Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L

Figure 2 Comparison between noncarriers (−) and carriers (+) of the minor allele of rs (CYP2C19)‏ Comparison between noncarriers (−) and carriers.

UC Davis Data Summary Psychometrics 2018.

*****For more information, please call*****

Schematic overview of the immuno‐infrared‐sensor, the assay read‐out, and BioFINDER and ESTHER study design Schematic overview of the immuno‐infrared‐sensor,

ADNI 3 UPDATE MICHAEL WEINER.

Columbia University Medical Center

in Younger and Older African Americans and Whites

Presentation transcript:

Table 2. Data Sharing for (Reporting Period) Number of studies receiving ADC resources Funding source Request Type Federal Non-federal Industry Total Data Only (including APOE and Imaging) Tissue (including DNA, CSF, fibroblasts, and brain) Participant Requests

Table 3. ADC Productivity During (Reporting Period) XX center-supported publications YY studies supported with data, tissue or participants ZZ trainees on K awards or other training grants XYZ continuing multi-site collaborations (NACC, NCRAD, ADCS, ATRI, ADNI, LOAD, ADGC, GAP, IDEAS) Other collaborations Externally funded grant awards

Table 4. ADC Pilot Grant Program for (Reporting Period) XX applications from YY departments: Genetics, Neurology, Psychiatry, Biomedical Engineering, etc List each Pilot Grant #, name/degree/department of awardee, and Pilot Grant title for each application selected for funding by the ADC’s Executive Committee Indicate if any Pilots are being funded with resources other than the ADC budget

Table 5a. ADC Active Cohort (N = XXX) CDR 0 N= CDR 0.5 CDR 1 Age (y) Education (y) Male (%) African American (%) MMSE % with APOE4 allele Note: Other variables may be incorporated; for example, some ADCs may wish to replace the MMSE with the MoCA. Also, the summary statistics may include the clinical diagnoses of individuals who are cognitively impaired (see Table 5b).

Table 5b. ADC Active Cohort (N = XXX) Disorder/Syndrome (D1) N= MCI Amnestic dementia PCA PPA bvFTD DLB Nonamnestic multidomain Other Etiology (D1) N= AD LBD MSA PSP CBD FTLD-MND FTLD-NOS Vascular Note: Data can be pulled from NACC Form D1

Table 6. Autopsy Rate (Reporting Period) ADC Participants (everyone with one or more ADC clinical assessment) XX autopsies in YY deaths; XX/YY = ZZ%

Table 7. ADC Participation in Study Procedures (ever in active participants) 2015 2016 2017 Amyloid PET imaging CSF MRI Blood for Genetics Note: If other biomarkers variables are obtained by the ADC, they also should be included (eg, tau PET imaging; fibroblast collection for generation of induced pluripotent stem cells, etc).